Market cap
$5,512 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-223 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.7
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$-1.7
-
Face value
--
-
Shares outstanding
137,976,992
10 Years Aggregate
CFO
$-665.46 Mln
EBITDA
$-726.95 Mln
Net Profit
$-704.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IVERIC bio (ISEE)
| 86.6 | 4.8 | 46.7 | 241.2 | 108.3 | 71.2 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
IVERIC bio (ISEE)
| 28.1 | 142.0 | -19.5 | 615.0 | -61.3 | -35.4 | -93.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IVERIC bio (ISEE)
|
40.0 | 5,512.2 | 0.0 | -212.1 | -- | -57.6 | -- | 3.8 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout IVERIC bio (ISEE)
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has... completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc. Read more
-
CEO & Director
Mr. Glenn P. Sblendorio M.B.A.
-
CEO & Director
Mr. Glenn P. Sblendorio M.B.A.
-
Headquarters
Parsippany, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for IVERIC bio (ISEE)
What is the current share price of IVERIC bio Inc (ISEE) Today?
The share price of IVERIC bio Inc (ISEE) is $39.95 (NASDAQ) as of 11-Jul-2023 09:30 EDT. IVERIC bio Inc (ISEE) has given a return of 108.3% in the last 3 years.
What is the current PB & PE ratio of IVERIC bio Inc (ISEE)?
Since, TTM earnings of IVERIC bio Inc (ISEE) is negative, P/E ratio is not available.
The P/B ratio of IVERIC bio Inc (ISEE) is 3.81 times as on 11-Jul-2023, a 29 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-15.27 |
5.02 |
2021 |
-16.84 |
5.34 |
2020 |
-7.59 |
3.35 |
2019 |
-6.47 |
3.25 |
2018 |
0.75 |
0.38 |
What is the 52 Week High and Low of IVERIC bio Inc (ISEE)?
The 52-week high and low of IVERIC bio Inc (ISEE) are Rs -- and Rs -- as of 30-Aug-2026.
What is the market cap of IVERIC bio Inc (ISEE)?
IVERIC bio Inc (ISEE) has a market capitalisation of $ 5,512 Mln as on 11-Jul-2023. As per SEBI classification, it is a company.
Should I invest in IVERIC bio Inc (ISEE)?
Before investing in IVERIC bio Inc (ISEE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.